By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
IndebtaIndebta
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
9
Notification Show More
Videos
Tesla is a company entering, ‘a golden age,’ Wedbush’s Dan Ives says
2 hours ago
Videos
Why manufacturing is so hard in the U.S.
2 hours ago
News
Intrusion Inc. (INTZ) Q2 2025 Earnings Call Transcript
2 hours ago
Videos
LIVE: President Trump visits the Federal Reserve
1 day ago
Videos
How Blackstone became a major U.S. landlord
1 day ago
News
Mercury Systems, Inc. (MRCY) Q4 2025 Earnings Call Transcript
1 day ago
Videos
Why this investor says Opendoor is not a meme stock
2 days ago
Videos
Why Claire’s Keeps Filing For Bankruptcy
2 days ago
News
RGA Investment Advisors Q2 2025  Investment Commentary
2 days ago
Aa
IndebtaIndebta
Aa
  • Banking
  • Credit Cards
  • Loans
  • Dept Management
  • Mortgage
  • Markets
  • Investing
  • Small Business
  • Videos
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Follow US
Indebta > Markets > Forex > Ironwood bulks up on digestive therapies with $1.15 billion VectivBio buy
Forex

Ironwood bulks up on digestive therapies with $1.15 billion VectivBio buy

News Room
Last updated: 2023/05/22 at 2:00 PM
By News Room
Share
2 Min Read
SHARE

By Raghav Mahobe

(Reuters) -Ironwood Pharmaceuticals Inc said on Monday it would buy Switzerland-based drug developer VectivBio Holding AG for $1.15 billion, adding a promising treatment for digestive disorders to its portfolio.

Ironwood has offered $17 per share for VectivBio, a premium of about 43% to the stock’s last close.

VectivBio’s shares were at $16.21 in morning trade, while Ironwood’s stock fell 4.5% to $10.

The deal, expected to close in the second half, will help ease Massachusetts-based Ironwood’s dependence on bowel disease drug Linzess, which it sells along with AbbVie (NYSE:).

AbbVie reported first-quarter U.S. sales of $250.2 million from Linzess.

VectivBio is developing apraglutide for a type of short bowel syndrome, where the body is unable to properly absorb nutrients and can be potentially fatal.

Data from a late-stage study is expected by year-end.

Ironwood hopes the treatment will become a blockbuster therapy, banking on a longer dosing interval and potentially better effectiveness to help it compete against other treatments.

“There’s certainly challenges with daily injections versus a once-week injection. But I think what’s going to really drive it (apraglutide) is the overall efficacy of the drug,” Ironwood CEO Thomas McCourt said in a conference call.

The deal would add to its earnings from 2026, Ironwood added, with a successful commercialization of the therapy.

The disease has an estimated addressable population of 18,000 adult patients in the U.S., Europe and Japan, according to the companies.

Apraglutide belongs to a class of treatments known as GLP-2s, which includes Takeda Pharmaceutical’s Gattex that is already approved to treat short bowel syndrome and needs to be injected daily.

Read the full article here

News Room May 22, 2023 May 22, 2023
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Finance Weekly Newsletter

Join now for the latest news, tips, and analysis about personal finance, credit cards, dept management, and many more from our experts.
Join Now
Tesla is a company entering, ‘a golden age,’ Wedbush’s Dan Ives says

Watch full video on YouTube

Why manufacturing is so hard in the U.S.

Watch full video on YouTube

Intrusion Inc. (INTZ) Q2 2025 Earnings Call Transcript

Intrusion Inc. (NASDAQ:INTZ) Q2 2025 Earnings Conference Call August 12, 2025 5:00…

LIVE: President Trump visits the Federal Reserve

Watch full video on YouTube

How Blackstone became a major U.S. landlord

Watch full video on YouTube

- Advertisement -
Ad imageAd image

You Might Also Like

Forex

Thailand’s weakening baht not all bad for economy – PM

By News Room
Forex

Sterling hits multi-month low, Fed holds rates steady amid inflation concerns

By News Room
Forex

Dollar index on verge of forming bullish ‘golden cross’ – BofA

By News Room
Forex

Japan warns against post-Fed yen slide

By News Room
Forex

Asian currencies stumble amid rising U.S. dollar and hawkish Federal Reserve stance

By News Room
Forex

Asian currencies under pressure due to Federal Reserve’s stance, says HSBC

By News Room
Forex

Dollar rallies, yen under pressure ahead of BOJ rate decision

By News Room
Forex

Gambia’s dalasi remains Africa’s strongest currency amid tourism and remittance inflows

By News Room
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Press Release
  • Contact
  • Advertisement
More Info
  • Newsletter
  • Market Data
  • Credit Cards
  • Videos

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions
Join Community

2023 © Indepta.com. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?